Global Human Milk Oligosaccharides (HMO) Market-Industry Analysis and Forecast (2020-2027) – By Product, By Type, By Application, and By Geography

Global Human Milk Oligosaccharides (HMO) Market size is expected to reach nearly US$ 101.6 Mn by 2027 with the CAGR of 14.6% during the forecast period.

• Demand Side Drivers:

o Increasing concerns among consumers regarding gut health including bacteria, archaea and fungi are the key drivers resulting market to reach USD XX Mn globally by 2027. o Europe dominated the Human Milk Oligosaccharides (HMO) Market with a share of 42.18% in the year 2019.

• Supply Side Drivers:

o The market is driven by large players meeting xx% of the demand, which include manufacturers, supplier, and distributors. These players are pushing multiple offerings at different price points. o Dutch multinational corporation (DSM) would acquire Glycom for $830 million, a Danish company, one of the leading supplier of human milk oligosaccharides (HMOs). With the acquisition, DSM will follow firms like BASF and DuPont, to expand its business presence in the next 5 years. o According to DSM, the global HMO market is currently around US$ 110 million per year and growing rapidly. Glycom reported $80 million in sales in 2019, mostly to Nestlé, which is a large investor in Glycom. Drivers: Growing consumption of dietary supplements, encourage optimal health and help to prevent certain diseases, help to improve the brain development and enhance memory power, the demand of HMO in infant formula, market players are increasingly investing in the R&D activities, and among others are the key factors resulting the market to grow at a CAGR of 24.1% by 2027.

Rising Demand for HMO in Infant Formula:

The human milk oligosaccharides (HMO) market is poised to receive an upsurge because of useful properties like infection prevention, brain development and memory enhancement in humans, prebiotic effects, and improvement of intestinal health, the demand for HMOs in the design of infant formulas is growing. For instance, in June 2018, Abbott announced its new infant formula product, Similac Eye-Q Plus with human milk oligosaccharides (HMO), in Vietnam. The addition of HMOs in functional food & beverage products supports the growth of good bacteria and can also eliminate harmful bacteria such as salmonella and campylobacter. The fast-rising health awareness among people in emerging countries like China and India is expected to boost market growth during the forecast period (2020-2027). For instance, in April 2019, Nestle S.A., presented three new products in the U.K., specifically, SMA Advanced Follow-on Formula, SMA Advanced Growing up Milk, and SMA Advanced Infant Formula. These products contained artificial HMOs and were planned for infants who were not breastfed. Such growths within the infant formula sector are expected to drive the demand for human milk oligosaccharides (HMO) in the current future. Restraint: Lack of technology for large-scale production, high R&D cost, limited production, and stringent government regulations are likely to restrain the HMO market growth.

High Cost of Product Due to Expensive Manufacturing Process:

The low availability of a group of donors, and HMO cannot be produced directly from human milk are the key restraints for the growth of the human milk oligosaccharides (HMO) market. Now, producers are emerging technologies through chemical and enzymatic synthesis to generate human milk oligosaccharides (HMO). These synthetic and enzymatic methods need a high amount of capital and energy, but the production of the final product is comparatively low. For example, for costly substrates like glycosyltransferases, enzymatic synthesis is required and this is one of the main factors due to the high price of oligosaccharides of human milk.

Global Human Milk Oligosaccharides (HMO) Market Opportunities:

The growing concerns among consumers about gut health and the consumption of dietary supplements is expected to generate significant opportunities for the HMO Market. For instance, DuPont Nutrition & Health's CARE4U is used as a dietary supplement ingredient. The market viewing strong competition because of the increasing number of market entrants. Human milk oligosaccharides (HMOs) act as prebiotics in the human body and support to maintain gut health. They encourage bacterial growth, particularly bifidobacteria genus, in the gut, which helps improve metabolic activity.

Covid-19 Impact on the Human Milk Oligosaccharides (HMO) Market:

• The Covid-19 impact on the market like food production and delivery systems can be disrupted. Recent challenges in food like human milk oligosaccharides (HMO) supply-chain, there is now significant concern about human milk oligosaccharides (HMO) production, processing, distribution, and demand. • COVID-19 resulted in the movement restrictions of workers, fluctuations in demand of consumers, closure of food production facilities, restricted food trade policies, and financial pressures in the food supply chain. Facilities should change the working conditions and maintain the health and safety of employees by altering safety measures. Food companies face several challenges due to a drop in income, while others are working hard to meet the growing demand of retailers.

Global Human Milk Oligosaccharides (HMO) Market Segment Analysis

By Product, Lacto-N-neotetraose segment accounted for the largest market share in 2019

Lacto-N-neotetraose segment accounted for the largest market share of the global market in 2019. This is mainly due to the increasing growth of useful bifidobacteria and decreasing the growth of pathogenic bacteria which is ultimately appealing to the producers of food & beverages and food supplements. But, 2'-Fucosyllactose (2'FL) segment is expected to hold the highest CAGR of XX% during the forecast period (2020-2027). Producers of dietary supplements are shifting towards 2’-fucosyllactose (2’FL) because of its capability of changing the composition and activity of gut microbiota from formula-fed infants receiving complementary feeding and its support the development of a healthy gut, which is likely to push the growth of the human milk oligosaccharides (HMO) market. Global Human Milk Oligosaccharides (HMO) Market To know about the Research Methodology :- Request Free Sample Report

By Application, Infant Formulas application accounted for the largest market share in 2019

Infant Formulas application accounted for the largest market share in 2019 and is expected to hold steady dominance in the forecasted period (2020-2027). This is mainly due to the growing middle-class family unit and the numerous working women are the key factors increasing the demand for human milk oligosaccharides (HMOs) in infant formulas. Likewise, the demand for human milk oligosaccharides (HMOs) in infant formulas is increasing as it encourages infant health by supporting digestive, immune, and intellectual improvement.

Global Human Milk Oligosaccharides (HMO) Market Regional Insights:

Europe is expected to account for the largest market during the forecast period in terms of value. Europe is the key region dominating the human milk oligosaccharides (HMO) market with a revenue share of 42.15% in 2019. This is mainly because of the occurrence of various prominent infant formula and baby food producers with technological advancement. The country in Europe like the UK has recorded the lowest rate for breastfeeding. This is mainly because of the increasing rate of working women population and cuts in public health funding. Asia Pacific region is expected to be the fastest growing region with highest CAGR of XX% during the forecast period. Asia Pacific region is expected to be the fastest-growing region with the highest CAGR of XX% during the forecast period 2020-2025. This is mainly because of the rising population, mortality rate, disposable income, and consumer alertness about health and hygiene. Growing concerns regarding gut diseases, high blood pressure, and diabetes. The developing economies such as China and India are the emerging markets for baby foods and dietary supplements.

The objective of the report is to provide the following:

• To provide market size, forecast data for global, regional and market segments • To provide strategic developments, benchmarking and market share analysis of 10 players operating in the global human milk oligosaccharides (HMOs) market • Detailed insights on drivers, restraints, opportunities, and challenges in the human milk oligosaccharides (HMOs) industry • Impact of technological advancements in the human milk oligosaccharides (HMOs) market and its future outlook • High level insights on the regional and country level analysis along with regional attractiveness • Market intelligence on the growth trends and opportunity analysis in the human milk oligosaccharides (HMOs) market at the segmental and overall market levels • In-depth coverage of SWOT, PORTER, PEST and VALUE & SUPPLY CHAIN

Scope of the Global Human Milk Oligosaccharides (HMO) Market: Inquire before buying

Global Human Milk Oligosaccharides (HMO) Market, By Product

• Lacto-N-neotetraose (LNnT) • Lacto-N-tetraose (LNT) • 2'-Fucosyllactose (2'FL) • 3'-Fucosyllactose (3'FL) • 3'-Sialyllactose (3'SL) • 6'-Sialyllactose (6'SL) • Others

Global Human Milk Oligosaccharides (HMO) Market, By Type

• Neutral • Acidic

Global Human Milk Oligosaccharides (HMO) Market, By Application

• Food & beverages • Food supplements • Infant formulas • Others

Global Human Milk Oligosaccharides (HMO) Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Human Milk Oligosaccharides (HMO) Market

• Elicityl SA • Medolac Laboratories • Inbiose • Glycosyn • ZuChem • Jennewein Biotechnologie • Glycom • Abbott • BASF S.E • Dupont De Nemours Inc • Royal FrieslandCampina N.V • Others
Global Human Milk Oligosaccharides (HMO) Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Forms 2.3.2. Primary Research 2.3.2.1. Data from Primary Forms 2.3.2.2. Breakdown of Primary Forms 3. Executive Summary: Global Human Milk Oligosaccharides (HMO) Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast 6.1. Human Milk Oligosaccharides (HMO) Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 7.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Application 7.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Application 7.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Application 8. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Product 8.1. Introduction and Definition 8.2. Key Findings 8.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 8.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Product 8.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Product 8.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Product 9. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 9.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Type 9.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Type 9.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Type 10. Global Human Milk Oligosaccharides (HMO) Market Analysis, by Region 10.1. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Region 10.2. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, by Region 10.3. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, by Region 11. North America Human Milk Oligosaccharides (HMO) Market Analysis 11.1. Key Findings 11.2. North America Human Milk Oligosaccharides (HMO) Market Overview 11.3. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 11.4. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Application 11.4.1. Food & beverages 11.4.2. Food supplements 11.4.3. Infant formulas 11.4.4. Others 11.5. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 11.6. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Product 11.6.1. Lacto-N-neotetraose (LNnT) 11.6.2. Lacto-N-tetraose (LNT) 11.6.3. 2'-Fucosyllactose (2'FL) 11.6.4. 3'-Fucosyllactose (3'FL) 11.6.5. 3'-Sialyllactose (3'SL) 11.6.6. 6'-Sialyllactose (6'SL) 11.6.7. Others 11.7. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 11.8. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Type 11.8.1. Neutral 11.8.2. Acidic 11.9. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country 11.10. North America Human Milk Oligosaccharides (HMO) Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Human Milk Oligosaccharides (HMO) Market Analysis, by Country 11.12. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Application 11.12.1. Food & beverages 11.12.2. Food supplements 11.12.3. Infant formulas 11.12.4. Others 11.13. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Product 11.13.1. Lacto-N-neotetraose (LNnT) 11.13.2. Lacto-N-tetraose (LNT) 11.13.3. 2'-Fucosyllactose (2'FL) 11.13.4. 3'-Fucosyllactose (3'FL) 11.13.5. 3'-Sialyllactose (3'SL) 11.13.6. 6'-Sialyllactose (6'SL) 11.13.7. Others 11.14. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Type 11.14.1. Neutral 11.14.2. Acidic 11.15. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Application 11.15.1. Food & beverages 11.15.2. Food supplements 11.15.3. Infant formulas 11.15.4. Others 11.16. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Product 11.16.1. Lacto-N-neotetraose (LNnT) 11.16.2. Lacto-N-tetraose (LNT) 11.16.3. 2'-Fucosyllactose (2'FL) 11.16.4. 3'-Fucosyllactose (3'FL) 11.16.5. 3'-Sialyllactose (3'SL) 11.16.6. 6'-Sialyllactose (6'SL) 11.16.7. Others 11.17. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Type 11.17.1. Neutral 11.17.2. Acidic 11.18. North America Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis 11.18.1. By Application 11.18.2. By Product 11.18.3. By Type 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Human Milk Oligosaccharides (HMO) Market Analysis 12.1. Key Findings 12.2. Europe Human Milk Oligosaccharides (HMO) Market Overview 12.3. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 12.4. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.4.1. Food & beverages 12.4.2. Food supplements 12.4.3. Infant formulas 12.4.4. Others 12.5. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 12.6. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.6.1. Lacto-N-neotetraose (LNnT) 12.6.2. Lacto-N-tetraose (LNT) 12.6.3. 2'-Fucosyllactose (2'FL) 12.6.4. 3'-Fucosyllactose (3'FL) 12.6.5. 3'-Sialyllactose (3'SL) 12.6.6. 6'-Sialyllactose (6'SL) 12.6.7. Others 12.7. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 12.8. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.8.1. Neutral 12.8.2. Acidic 12.9. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country 12.10. Europe Human Milk Oligosaccharides (HMO) Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Russia 12.11. Europe Human Milk Oligosaccharides (HMO) Market Analysis, by Country 12.12. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.12.1. Food & beverages 12.12.2. Food supplements 12.12.3. Infant formulas 12.12.4. Others 12.13. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.13.1. Lacto-N-neotetraose (LNnT) 12.13.2. Lacto-N-tetraose (LNT) 12.13.3. 2'-Fucosyllactose (2'FL) 12.13.4. 3'-Fucosyllactose (3'FL) 12.13.5. 3'-Sialyllactose (3'SL) 12.13.6. 6'-Sialyllactose (6'SL) 12.13.7. Others 12.14. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.14.1. Neutral 12.14.2. Acidic 12.15. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.15.1. Food & beverages 12.15.2. Food supplements 12.15.3. Infant formulas 12.15.4. Others 12.16. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.16.1. Lacto-N-neotetraose (LNnT) 12.16.2. Lacto-N-tetraose (LNT) 12.16.3. 2'-Fucosyllactose (2'FL) 12.16.4. 3'-Fucosyllactose (3'FL) 12.16.5. 3'-Sialyllactose (3'SL) 12.16.6. 6'-Sialyllactose (6'SL) 12.16.7. Others 12.17. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.17.1. Neutral 12.17.2. Acidic 12.18. France Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.18.1. Food & beverages 12.18.2. Food supplements 12.18.3. Infant formulas 12.18.4. Others 12.19. France Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.19.1. Lacto-N-neotetraose (LNnT) 12.19.2. Lacto-N-tetraose (LNT) 12.19.3. 2'-Fucosyllactose (2'FL) 12.19.4. 3'-Fucosyllactose (3'FL) 12.19.5. 3'-Sialyllactose (3'SL) 12.19.6. 6'-Sialyllactose (6'SL) 12.19.7. Others 12.20. France Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.20.1. Neutral 12.20.2. Acidic 12.21. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.21.1. Food & beverages 12.21.2. Food supplements 12.21.3. Infant formulas 12.21.4. Others 12.22. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.22.1. Lacto-N-neotetraose (LNnT) 12.22.2. Lacto-N-tetraose (LNT) 12.22.3. 2'-Fucosyllactose (2'FL) 12.22.4. 3'-Fucosyllactose (3'FL) 12.22.5. 3'-Sialyllactose (3'SL) 12.22.6. 6'-Sialyllactose (6'SL) 12.22.7. Others 12.23. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.23.1. Neutral 12.23.2. Acidic 12.24. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.24.1. Food & beverages 12.24.2. Food supplements 12.24.3. Infant formulas 12.24.4. Others 12.25. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.25.1. Lacto-N-neotetraose (LNnT) 12.25.2. Lacto-N-tetraose (LNT) 12.25.3. 2'-Fucosyllactose (2'FL) 12.25.4. 3'-Fucosyllactose (3'FL) 12.25.5. 3'-Sialyllactose (3'SL) 12.25.6. 6'-Sialyllactose (6'SL) 12.25.7. Others 12.26. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.26.1. Neutral 12.26.2. Acidic 12.27. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.27.1. Food & beverages 12.27.2. Food supplements 12.27.3. Infant formulas 12.27.4. Others 12.28. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.28.1. Lacto-N-neotetraose (LNnT) 12.28.2. Lacto-N-tetraose (LNT) 12.28.3. 2'-Fucosyllactose (2'FL) 12.28.4. 3'-Fucosyllactose (3'FL) 12.28.5. 3'-Sialyllactose (3'SL) 12.28.6. 6'-Sialyllactose (6'SL) 12.28.7. Others 12.29. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.29.1. Neutral 12.29.2. Acidic 12.30. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Application 12.30.1. Food & beverages 12.30.2. Food supplements 12.30.3. Infant formulas 12.30.4. Others 12.31. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Product 12.31.1. Lacto-N-neotetraose (LNnT) 12.31.2. Lacto-N-tetraose (LNT) 12.31.3. 2'-Fucosyllactose (2'FL) 12.31.4. 3'-Fucosyllactose (3'FL) 12.31.5. 3'-Sialyllactose (3'SL) 12.31.6. 6'-Sialyllactose (6'SL) 12.31.7. Others 12.32. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Type 12.32.1. Neutral 12.32.2. Acidic 12.33. Europe Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis 12.33.1. By Application 12.33.2. By Product 12.33.3. By Type 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Developments 13. Asia Pacific Human Milk Oligosaccharides (HMO) Market Analysis 13.1. Key Findings 13.2. Asia Pacific Human Milk Oligosaccharides (HMO) Market Overview 13.3. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 13.4. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.4.1. Food & beverages 13.4.2. Food supplements 13.4.3. Infant formulas 13.4.4. Others 13.5. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 13.6. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.6.1. Lacto-N-neotetraose (LNnT) 13.6.2. Lacto-N-tetraose (LNT) 13.6.3. 2'-Fucosyllactose (2'FL) 13.6.4. 3'-Fucosyllactose (3'FL) 13.6.5. 3'-Sialyllactose (3'SL) 13.6.6. 6'-Sialyllactose (6'SL) 13.6.7. Others 13.7. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 13.8. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.8.1. Neutral 13.8.2. Acidic 13.9. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country 13.10. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.11. Asia Pacific Human Milk Oligosaccharides (HMO) Market Analysis, by Country 13.12. China Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.12.1. Food & beverages 13.12.2. Food supplements 13.12.3. Infant formulas 13.12.4. Others 13.13. China Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.13.1. Lacto-N-neotetraose (LNnT) 13.13.2. Lacto-N-tetraose (LNT) 13.13.3. 2'-Fucosyllactose (2'FL) 13.13.4. 3'-Fucosyllactose (3'FL) 13.13.5. 3'-Sialyllactose (3'SL) 13.13.6. 6'-Sialyllactose (6'SL) 13.13.7. Others 13.14. China Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.14.1. Neutral 13.14.2. Acidic 13.15. India Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.15.1. Food & beverages 13.15.2. Food supplements 13.15.3. Infant formulas 13.15.4. Others 13.16. India Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.16.1. Lacto-N-neotetraose (LNnT) 13.16.2. Lacto-N-tetraose (LNT) 13.16.3. 2'-Fucosyllactose (2'FL) 13.16.4. 3'-Fucosyllactose (3'FL) 13.16.5. 3'-Sialyllactose (3'SL) 13.16.6. 6'-Sialyllactose (6'SL) 13.16.7. Others 13.17. India Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.17.1. Neutral 13.17.2. Acidic 13.18. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.18.1. Food & beverages 13.18.2. Food supplements 13.18.3. Infant formulas 13.18.4. Others 13.19. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.19.1. Lacto-N-neotetraose (LNnT) 13.19.2. Lacto-N-tetraose (LNT) 13.19.3. 2'-Fucosyllactose (2'FL) 13.19.4. 3'-Fucosyllactose (3'FL) 13.19.5. 3'-Sialyllactose (3'SL) 13.19.6. 6'-Sialyllactose (6'SL) 13.19.7. Others 13.20. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.20.1. Neutral 13.20.2. Acidic 13.21. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.21.1. Food & beverages 13.21.2. Food supplements 13.21.3. Infant formulas 13.21.4. Others 13.22. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.22.1. Lacto-N-neotetraose (LNnT) 13.22.2. Lacto-N-tetraose (LNT) 13.22.3. 2'-Fucosyllactose (2'FL) 13.22.4. 3'-Fucosyllactose (3'FL) 13.22.5. 3'-Sialyllactose (3'SL) 13.22.6. 6'-Sialyllactose (6'SL) 13.22.7. Others 13.23. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.23.1. Neutral 13.23.2. Acidic 13.24. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.24.1. Food & beverages 13.24.2. Food supplements 13.24.3. Infant formulas 13.24.4. Others 13.25. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.25.1. Lacto-N-neotetraose (LNnT) 13.25.2. Lacto-N-tetraose (LNT) 13.25.3. 2'-Fucosyllactose (2'FL) 13.25.4. 3'-Fucosyllactose (3'FL) 13.25.5. 3'-Sialyllactose (3'SL) 13.25.6. 6'-Sialyllactose (6'SL) 13.25.7. Others 13.26. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.26.1. Neutral 13.26.2. Acidic 13.27. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.27.1. Food & beverages 13.27.2. Food supplements 13.27.3. Infant formulas 13.27.4. Others 13.28. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.28.1. Lacto-N-neotetraose (LNnT) 13.28.2. Lacto-N-tetraose (LNT) 13.28.3. 2'-Fucosyllactose (2'FL) 13.28.4. 3'-Fucosyllactose (3'FL) 13.28.5. 3'-Sialyllactose (3'SL) 13.28.6. 6'-Sialyllactose (6'SL) 13.28.7. Others 13.29. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.29.1. Neutral 13.29.2. Acidic 13.30. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.30.1. Food & beverages 13.30.2. Food supplements 13.30.3. Infant formulas 13.30.4. Others 13.31. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.31.1. Lacto-N-neotetraose (LNnT) 13.31.2. Lacto-N-tetraose (LNT) 13.31.3. 2'-Fucosyllactose (2'FL) 13.31.4. 3'-Fucosyllactose (3'FL) 13.31.5. 3'-Sialyllactose (3'SL) 13.31.6. 6'-Sialyllactose (6'SL) 13.31.7. Others 13.32. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.32.1. Neutral 13.32.2. Acidic 13.33. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Application 13.33.1. Food & beverages 13.33.2. Food supplements 13.33.3. Infant formulas 13.33.4. Others 13.34. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Product 13.34.1. Lacto-N-neotetraose (LNnT) 13.34.2. Lacto-N-tetraose (LNT) 13.34.3. 2'-Fucosyllactose (2'FL) 13.34.4. 3'-Fucosyllactose (3'FL) 13.34.5. 3'-Sialyllactose (3'SL) 13.34.6. 6'-Sialyllactose (6'SL) 13.34.7. Others 13.35. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Type 13.35.1. Neutral 13.35.2. Acidic 13.36. Asia Pacific Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis 13.36.1. By Application 13.36.2. By Product 13.36.3. By Type 13.37. PEST Analysis 13.38. Key Trends 13.39. Key Developments 14. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Overview 14.3. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 14.4. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Application 14.4.1. Food & beverages 14.4.2. Food supplements 14.4.3. Infant formulas 14.4.4. Others 14.5. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 14.6. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Product 14.6.1. Lacto-N-neotetraose (LNnT) 14.6.2. Lacto-N-tetraose (LNT) 14.6.3. 2'-Fucosyllactose (2'FL) 14.6.4. 3'-Fucosyllactose (3'FL) 14.6.5. 3'-Sialyllactose (3'SL) 14.6.6. 6'-Sialyllactose (6'SL) 14.6.7. Others 14.7. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 14.8. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Type 14.8.1. Neutral 14.8.2. Acidic 14.9. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country 14.10. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.11. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Analysis, by Country 14.12. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Application 14.12.1. Food & beverages 14.12.2. Food supplements 14.12.3. Infant formulas 14.12.4. Others 14.13. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Product 14.13.1. Lacto-N-neotetraose (LNnT) 14.13.2. Lacto-N-tetraose (LNT) 14.13.3. 2'-Fucosyllactose (2'FL) 14.13.4. 3'-Fucosyllactose (3'FL) 14.13.5. 3'-Sialyllactose (3'SL) 14.13.6. 6'-Sialyllactose (6'SL) 14.13.7. Others 14.14. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Type 14.14.1. Neutral 14.14.2. Acidic 14.15. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Application 14.15.1. Food & beverages 14.15.2. Food supplements 14.15.3. Infant formulas 14.15.4. Others 14.16. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Product 14.16.1. Lacto-N-neotetraose (LNnT) 14.16.2. Lacto-N-tetraose (LNT) 14.16.3. 2'-Fucosyllactose (2'FL) 14.16.4. 3'-Fucosyllactose (3'FL) 14.16.5. 3'-Sialyllactose (3'SL) 14.16.6. 6'-Sialyllactose (6'SL) 14.16.7. Others 14.17. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Type 14.17.1. Neutral 14.17.2. Acidic 14.18. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Application 14.18.1. Food & beverages 14.18.2. Food supplements 14.18.3. Infant formulas 14.18.4. Others 14.19. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Product 14.19.1. Lacto-N-neotetraose (LNnT) 14.19.2. Lacto-N-tetraose (LNT) 14.19.3. 2'-Fucosyllactose (2'FL) 14.19.4. 3'-Fucosyllactose (3'FL) 14.19.5. 3'-Sialyllactose (3'SL) 14.19.6. 6'-Sialyllactose (6'SL) 14.19.7. Others 14.20. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Type 14.20.1. Neutral 14.20.2. Acidic 14.21. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Application 14.21.1. Food & beverages 14.21.2. Food supplements 14.21.3. Infant formulas 14.21.4. Others 14.22. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Product 14.22.1. Lacto-N-neotetraose (LNnT) 14.22.2. Lacto-N-tetraose (LNT) 14.22.3. 2'-Fucosyllactose (2'FL) 14.22.4. 3'-Fucosyllactose (3'FL) 14.22.5. 3'-Sialyllactose (3'SL) 14.22.6. 6'-Sialyllactose (6'SL) 14.22.7. Others 14.23. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Type 14.23.1. Neutral 14.23.2. Acidic 14.24. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis 14.24.1. By Application 14.24.2. By Product 14.24.3. By Type 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. South America Human Milk Oligosaccharides (HMO) Market Analysis 15.1. Key Findings 15.2. South America Human Milk Oligosaccharides (HMO) Market Overview 15.3. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application 15.4. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Application 15.4.1. Food & beverages 15.4.2. Food supplements 15.4.3. Infant formulas 15.4.4. Others 15.5. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product 15.6. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Product 15.6.1. Lacto-N-neotetraose (LNnT) 15.6.2. Lacto-N-tetraose (LNT) 15.6.3. 2'-Fucosyllactose (2'FL) 15.6.4. 3'-Fucosyllactose (3'FL) 15.6.5. 3'-Sialyllactose (3'SL) 15.6.6. 6'-Sialyllactose (6'SL) 15.6.7. Others 15.7. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type 15.8. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Type 15.8.1. Neutral 15.8.2. Acidic 15.9. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country 15.10. South America Human Milk Oligosaccharides (HMO) Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Argentina 15.11. South America Human Milk Oligosaccharides (HMO) Market Analysis, by Country 15.12. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Application 15.12.1. Food & beverages 15.12.2. Food supplements 15.12.3. Infant formulas 15.12.4. Others 15.13. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Product 15.13.1. Lacto-N-neotetraose (LNnT) 15.13.2. Lacto-N-tetraose (LNT) 15.13.3. 2'-Fucosyllactose (2'FL) 15.13.4. 3'-Fucosyllactose (3'FL) 15.13.5. 3'-Sialyllactose (3'SL) 15.13.6. 6'-Sialyllactose (6'SL) 15.13.7. Others 15.14. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Type 15.14.1. Neutral 15.14.2. Acidic 15.15. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Application 15.15.1. Food & beverages 15.15.2. Food supplements 15.15.3. Infant formulas 15.15.4. Others 15.16. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Product 15.16.1. Lacto-N-neotetraose (LNnT) 15.16.2. Lacto-N-tetraose (LNT) 15.16.3. 2'-Fucosyllactose (2'FL) 15.16.4. 3'-Fucosyllactose (3'FL) 15.16.5. 3'-Sialyllactose (3'SL) 15.16.6. 6'-Sialyllactose (6'SL) 15.16.7. Others 15.17. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Type 15.17.1. Neutral 15.17.2. Acidic 15.18. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Application 15.18.1. Food & beverages 15.18.2. Food supplements 15.18.3. Infant formulas 15.18.4. Others 15.19. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Product 15.19.1. Lacto-N-neotetraose (LNnT) 15.19.2. Lacto-N-tetraose (LNT) 15.19.3. 2'-Fucosyllactose (2'FL) 15.19.4. 3'-Fucosyllactose (3'FL) 15.19.5. 3'-Sialyllactose (3'SL) 15.19.6. 6'-Sialyllactose (6'SL) 15.19.7. Others 15.20. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Type 15.20.1. Neutral 15.20.2. Acidic 15.21. South America Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis 15.21.1. By Application 15.21.2. By Product 15.21.3. By Type 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Elicityl SA 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Medolac Laboratories 16.3.3. Inbiose 16.3.4. Glycosyn 16.3.5. ZuChem 16.3.6. Jennewein Biotechnologie 16.3.7. Glycom 16.3.8. Abbott 16.3.9. BASF S.E 16.3.10. Dupont De Nemours Inc 16.3.11. Royal FrieslandCampina N.V 16.3.12. Others 17. Primary Key Insights

About This Report

Report ID 80823
Category Food & Beverages
Published Date January 2021
Updated Date Oct 2021
Contact Us